



Open lecture



MEDICAL
UNIVERSITY
OF LODZ



Doctoral School of Molecular Medicine
Medical University of Lodz



International Doctoral School
Medical University of Lodz

Gene therapy for epidermolysis bullosa



M. Peter Marinkovich, MD

- Director of the Clinic for Bullous Diseases and Professor of Dermatology Stanford University School of Medicine

Dr. Marinkovich received his dermatology training at Oregon Health Sciences University, and his research training in the laboratory of Dr. Robert Burgeson on discovery/characterization of type VII collagen, the target of dystrophic epidermolysis bullosa and laminin-332 the target in most cases of junctional epidermolysis bullosa. Dr. Marinkovich later joined the faculty at Stanford University and the National Epidermolysis Bullosa Registry. Dr. Marinkovich directs the Bullous Diseases Clinic at Stanford, where he is known as one of the leading epidermolysis bullosa clinical experts, as well as a Bullous

Diseases Laboratory, where he has been a leader in the study of basement membrane biology and molecular therapy of epidermolysis bullosa. His group has taken the three leading dystrophic epidermolysis bullosa gene therapy programs from preclinical to phase 3 clinical trials including an autologous gene therapy skin graft technology licensed to Abeona Therapeutics, an autologous fibroblast gene therapy in partnership with CastleCreek, and a topical gene therapy in partnership with Krystal Biotech. The latter study, published in Nature Medicine and the New England Journal of Medicine in 2022, became first FDA approved gene therapy for epidermolysis bullosa in May 2023.

24.03.2025 • 12:00

Western Lecture Hall

Clinical and Didactic Centre
Medical University of Lodz
251 Pomorska St., Lodz, Poland



Dr. M. Peter Marinkovich will deliver this lecture at the invitation of the Department of Dermatology, Paediatric and Oncological Dermatology.